PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+6.01%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$2.87B
AUM Growth
+$2.87B
(+18%)
Cap. Flow
+$391M
Cap. Flow
% of AUM
13.62%
Top 10 Holdings %
Top 10 Hldgs %
38.22%
Holding
100
New
19
Increased
27
Reduced
20
Closed
13
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$103M |
| 2 |
Myriad Genetics
MYGN
|
$82.8M |
| 3 |
Baxter International
BAX
|
$38.7M |
| 4 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$33.5M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$33.2M |
Top Sells
| 1 |
Elevance Health
ELV
|
$52.7M |
| 2 |
iRhythm Technologies
IRTC
|
$40.6M |
| 3 |
Penumbra
PEN
|
$33.9M |
| 4 |
Bristol-Myers Squibb
BMY
|
$28M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$27.6M |
Sector Composition
| 1 | Healthcare | 93.52% |
| 2 | Financials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Outset Medical
OM
$247M
| $164M | 5% | 3,012,709 +101,502 | +3% | +$5.52M |
|
|
ALXN
2
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $162M | 4.95% | 1,059,631 +78,500 | +8% | +$12M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $146M | 4.46% | 1,587,348 +258,545 | +19% | +$23.8M |
|
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $103M | 3.13% | +1,055,510 | New | +$103M |
|
5
AbbVie
ABBV
$372B
| $100M | 3.06% | 926,823 | – | – |
|
6
Arcus Biosciences
RCUS
$1.13B
| $98.2M | 3% | 3,498,260 +124,800 | +4% | +$3.5M |
|
7
Eli Lilly
LLY
$657B
| $98.2M | 3% | 525,455 +174,810 | +50% | +$32.7M |
|
|
8
Myriad Genetics
MYGN
$593M
| $82.8M | 2.53% | +2,718,623 | New | +$82.8M |
|
9
HCA Healthcare
HCA
$94.5B
| $73.5M | 2.25% | 390,507 +77,020 | +25% | +$14.5M |
|
10
Gilead Sciences
GILD
$140B
| $69.5M | 2.12% | 1,075,063 +133,389 | +14% | +$8.62M |
|
11
McKesson
MCK
$85.4B
| $69.5M | 2.12% | 356,231 +47,244 | +15% | +$9.21M |
|
12
IQVIA
IQV
$32.4B
| $69.1M | 2.11% | 357,916 -15,385 | -4% | -$2.97M |
|
13
Universal Health Services
UHS
$11.6B
| $65M | 1.98% | 487,000 +44,956 | +10% | +$6M |
|
14
Avantor
AVTR
$9.18B
| $64.5M | 1.97% | 2,229,657 +155,398 | +7% | +$4.5M |
|
|
NVRO
15
DELISTED
NEVRO CORP.
NVRO
| $62.1M | 1.9% | 444,877 +132,937 | +43% | +$18.5M |
|
16
ICU Medical
ICUI
$3.15B
| $59.7M | 1.82% | 290,661 +22,844 | +9% | +$4.69M |
|
17
Humana
HUM
$36.5B
| $59.7M | 1.82% | 142,406 +64,666 | +83% | +$27.1M |
|
18
UnitedHealth
UNH
$281B
| $54.1M | 1.65% | 145,295 +43,196 | +42% | +$16.1M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $53.1M | 1.62% | 309,780 +100,774 | +48% | +$17.3M |
|
20
Edwards Lifesciences
EW
$47.8B
| $42.9M | 1.31% | 513,005 +25,163 | +5% | +$2.1M |
|
|
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
| $42.3M | 1.29% | 2,054,928 +1,008,716 | +96% | +$20.8M |
|
|
PPD
22
DELISTED
PPD, Inc. Common Stock
PPD
| $41.5M | 1.27% | 1,096,492 +353,629 | +48% | +$13.4M |
|
23
AstraZeneca
AZN
$248B
| $40.3M | 1.23% | 810,400 -284,200 | -26% | -$14.1M |
|
24
Danaher
DHR
$147B
| $39.5M | 1.21% | 175,690 +4,438 | +3% | +$999K |
|
|
25
Baxter International
BAX
$12.7B
| $38.7M | 1.18% | +458,476 | New | +$38.7M |
|